Quick Facts

• Hypovolemia: Used to help restore fluid volume following trauma, burns, or surgery.
• Microcirculation: May support blood flow in small vessels during certain surgical procedures.
• Thrombosis: Can be employed to assist in the prevention of clots, such as after surgical interventions.

---

ИНЪЕКТРАН is a prescription medication that may be used in several distinct clinical settings. Its primary therapeutic domain is in addressing hypovolemia, which is a significant decrease in the volume of blood plasma. It serves as a plasma volume expander, and its use may help to stabilize circulation and maintain blood flow following acute blood or fluid loss due to conditions like severe burns, major trauma, or surgical procedures.

Additionally, this product may be utilized to support microcirculation during vascular or microsurgical procedures. By influencing the flow properties of blood, it can help to maintain patency of small blood vessels. A further use includes contributing to the prophylactic management of thrombosis to assist in preventing the formation of clots, typically in patients who have undergone surgery. The use of this drug is determined by a healthcare professional based on a specific patient's clinical needs and presentation.

Regulatory References

1. NIH MedlinePlus guidance on Dextran

Population Eligibility for İNJEKTRAN (Dextran)

Eligibility for İNJEKTRAN (Dextran, a plasma volume expander) is strictly defined by regulatory documents, focusing on patient health status and age. The medicine is primarily used for patients with hypovolemia due to trauma or surgery and for thrombosis prophylaxis.

---

Absolute Contraindications

The medicine is absolutely contraindicated in patients with:

• A known hypersensitivity to dextran.
• Marked cardiac decompensation.
• Severe renal disease accompanied by oliguria or anuria (minimal or no urine output).
• Marked hemostatic defects of all types.

---

Conditional Use and Restrictions

Use is restricted or requires caution in several patient groups:

Population Group	Restriction Status
Neonates (Infants)	Safety and effectiveness have not been established.
Older Adults	Use requires caution due to increased risk of fluid overload.
Pregnancy	Should be given only if clearly needed.
Active Bleeding Risk	Use requires caution due to potential increased blood loss.
Renal Impairment	Use requires caution; excessive dosing risks precipitating renal failure.

These official rules define the specific physiological conditions and age thresholds that determine a patient’s non-eligibility or requirement for special oversight.

The interaction profile of İНЪЕКТРАН (Dextran 40) is primarily defined by additive effects on the body's systems and necessary procedural constraints, as documented in official regulatory sources.

Interactions with Medicines

The co-administration of this product with medicinal products that affect blood clotting, such as Warfarin or Heparin, carries a significant pharmacodynamic risk. The combination can result in an additive antihemostatic effect, which is restricted in clinical practice due to the potential for marked hemostatic defects. Separately, combining sodium-containing intravenous solutions with drugs that promote sodium retention, such as Corticosteroids or Corticotropin, increases the potential for fluid and solute overloading. This risk is specifically noted to be greater in patient populations with severe renal insufficiency or congestive heart failure.

Procedural and Timing Restrictions

Official labeling establishes mandatory timing rules due to the drug’s potential to interfere with laboratory diagnostic procedures. To ensure the accuracy of results, blood samples for tests like blood grouping, cross-matching, total protein, and bilirubin assays must be collected before the infusion of Dextran is initiated. A further restriction states that additive medications must not be delivered via the Dextran solution, defining an IV incompatibility. No specific interactions with food, alcohol, or herbal products are documented.

Pharmacodynamic Mechanism

The action of ИНЪЕКТРАН is centered on a tripartite mechanism within the articular cartilage and synovial environment. The molecule primarily acts as an enzyme inhibitor to suppress catabolism. It curtails the activity and synthesis of destructive enzymes, including Matrix Metalloproteinases (MMPs) and ADAMTS (Aggrecanases), which are responsible for the cleavage of structural proteins like Type II Collagen and Aggrecan. This interference with catabolic pathways contributes to the maintenance of the tissue's structural scaffolding.

Simultaneously, the drug functions as an anabolic stimulator by promoting the metabolic activity of chondrocytes. This cellular stimulation increases the synthesis and deposition of Proteoglycans into the extracellular matrix. The resulting increase in Proteoglycans enhances the tissue's capacity for water retention, which governs the elasticity and turgor of the cartilage and influences its viscoelastic properties.

The final component involves signaling modulation. The molecule suppresses the activation of the transcription factor NF-kappaB, thereby reducing the expression of pro-inflammatory mediators such as IL-1beta and COX-2. This modulation lowers the biochemical stress on chondrocytes, contributing to a reduction of localized catabolic stimuli.

Administration Scope and Official Protocol

ИНЪЕКТРАН (Chondroitin Sulfate Injection) is a parenteral medicine, meaning it is administered by injection. Official prescribing guidelines define two approved routes of administration: Intramuscular (IM) injection into the muscle, or Intra-articular (IA) injection into the joint space. The solution is ready-to-use and does not require dilution or other preparation prior to administration.

Labeled Dosing Schedule

The IM route follows a precise, fixed dosing protocol. Treatment is initiated with a lower dose of 100 mg (1 ml of 100 mg/ml solution). This starting dose is administered every other day for the first three injections.

Following the third dose, the regimen is increased to the standard maintenance dose of 200 mg (2 ml of solution). This 200 mg injection is continued every other day from the fourth dose onward, until the full course is completed. The IA route, which targets the joint, must be performed exclusively by a qualified specialist physician.

Use Cycles and Procedural Conditions

The overall use of this medicine is defined as a finite, cyclic course, not continuous long-term treatment. A complete course requires a total of 25 to 35 injections. Once this full course is completed, the protocol includes a rest period of at least six months before a repeat course is authorized. The standard adult regimen applies, as specific numerical dose adjustments for age, renal function, or hepatic function are not typically specified in the core prescribing information.

Evidence for Joint Structure and Function

Research exploring the compound in conditions associated with joint structural changes has utilized randomized controlled trials (RCTs) and systematic reviews. These studies primarily monitored patient-reported experiences, measuring physical discomfort and functional limitation indices, alongside objective markers like joint space width. Findings describe patterns related to outcomes of joint discomfort, but the evidence quality varies across studies. Because this compound was studied under the premise of a slow onset, monitoring required extended periods, and limited information exists to fully characterize long-term durability.

Evidence for Acute Volume and Circulation Support

A separate, long-established body of evidence, reviewed and accepted by regulatory bodies, pertains to the medicine’s profile in contexts related to acute circulatory function. Controlled clinical trials focused on temporary physiological imbalance in patients experiencing acute episodes like trauma or surgery. Studies monitored hemodynamic parameters (e.g., blood pressure) to track the evolution of circulatory function. Further research also explored the medicine’s profile for clot formation, monitoring the incidence of thromboembolic events in high-risk surgical patients. Findings were mixed in direct comparisons against certain other antithrombotic agents.

Research Gaps and Unanswered Questions

The available results apply only to the adult populations studied. Data for certain groups, including pediatric populations or subgroups defined by specific comorbid conditions, remain insufficient. Comparative evidence is lacking against many newest available treatments, and variability was observed in findings overall. Research provides context but not individual predictions, and the evidence indicates a need for harmonization of results across different trial designs.

Common questions about ИНЪЕКТРАН (FAQ)

Q: Is INJECTRAN a steroid?

According to the official product information, ИНЪЕКТРАН is classified as a corrector of bone and cartilage metabolism. Its active ingredient is Chondroitin sulfate. This medication is not classified in regulatory documents as a steroid.

Q: How does INJECTRAN differ from other joint injections?

Official documents classify this medicine based on its active ingredient, Chondroitin sulfate. It belongs to the pharmacological group known as symptomatic slow-acting drugs for osteoarthritis (SYSADOA). This classification indicates it is designed to support the underlying metabolic processes of the joint cartilage structure over time.

Q: Is INJECTRAN a painkiller?

The official mechanism of action focuses on supporting joint tissue and reducing inflammation within the joint structure. While research may note changes in patient-reported discomfort, the medication is not formally classified in regulatory documents as a direct pain reliever or analgesic.

Q: What does the “chondroprotective” action of INJECTRAN mean in simple terms?

The regulatory-described mechanism involves two main actions: slowing down the breakdown of cartilage and encouraging the cells to synthesize new structural components. This combined effect helps the joint tissue maintain its structural integrity and elasticity.

Q: How long does the effect last after completing the full course of INJECTRAN?

Official reviews and studies suggest that the compound is associated with a sustained duration of effect even after the treatment course is finished. However, official sources note that the data currently available to fully characterize the long-term durability of the effects are limited.

Q: Is it necessary to follow a specific diet or change lifestyle during the course of INJECTRAN?

Based on the official product information, there are no specific, mandatory requirements for a special diet or changes to general lifestyle that must be implemented while undergoing treatment with this medication.

Q: Can INJECTRAN be used for the prevention of joint problems?

The official therapeutic indications for the medicine relate to its use in chronic joint conditions to support cartilage integrity and function. Regulatory documentation does not specify its use for general prevention in individuals without an established condition.

Q: Is it allowed to self-administer INJECTRAN or must it be done only by a specialist?

Regulatory guidelines require that the intra-articular injection (into the joint space) be performed only by a qualified specialist physician. The intramuscular route (into the muscle) is a specialized parenteral procedure, and official documents advise that it should be performed by a healthcare professional.

Q: Is it true that INJECTRAN injections must be given at strictly the same time?

The official dosage schedule precisely defines the interval between injections, requiring administration every other day. However, the regulatory documents do not mandate that the injections must be carried out at a strictly uniform time of day.

Q: Why might the injection site turn red, sore, or swell after an INJECTRAN injection?

Like many injectable medications, the safety information for this product may include the possibility of common local reactions. These reactions can include temporary pain, redness, or swelling at the site where the injection was administered.

Q: Is INJECTRAN safe for older adults?

Official guidance addresses the use of the medicine in older adults. Caution is noted in this population due to the higher probability of age-related impairment in heart and kidney function, a general consideration for injectable solutions.

Q: Can INJECTRAN be used if the patient has chronic kidney disease?

Official safety documents state that the medication is generally contraindicated for patients with severe kidney failure. In cases of existing renal impairment, official product information indicates that caution is required.

Q: Can INJECTRAN cause habit formation or dependence?

Official regulatory documents regarding the active ingredient, Chondroitin sulfate, do not typically contain warnings or statements about the risk of abuse, physical dependence, or addiction.

Q: Is it possible to consume alcohol in moderation during treatment with INJECTRAN?

The official information on drug interactions states that no specific interactions between the medication and alcohol have been documented in regulatory sources.

Q: Can INJECTRAN be taken with popular vitamins or supplements?

Official regulatory documents state that no specific interactions have been documented with food or with herbal (plant-based) products.

Q: Is the simultaneous use of INJECTRAN and physiotherapy procedures safe?

Official product warnings and restrictions do not include guidance that prohibits the simultaneous use of the medication with standard physical therapy or rehabilitation procedures.

Q: Are there foods to avoid while being treated with INJECTRAN?

The official interaction profile of the product does not document any specific interactions with food items that must be avoided during the course of treatment.

Q: What are the results of long-term studies on the safety of INJECTRAN?

Due to the slow-acting nature of the compound, studies involved extended monitoring. However, official sources indicate that the information available to fully characterize the long-term safety and durability of the compound's effects is limited.

Q: Which international and national medical organizations approve the use of INJECTRAN?

The World Health Organization (WHO) identifies the active ingredient by assigning it the ATC code M01AX25. Its use is also recognized within recommendations for managing specific joint conditions, such as those published by the European League Against Rheumatism (EULAR).

Q: Is there evidence that INJECTRAN can slow the progression of joint disease?

Studies cited in regulatory documents investigate the product's effects on objective markers, such as joint space width, and on patient function indices. The focus of the research includes these structural and functional elements associated with chronic joint conditions.

Q: Why is INJECTRAN a prescription-only drug?

This medication is classified as a prescription-only pharmaceutical product. This status is typically required by national regulations due to the specialized method of administration (injection) and the need for professional oversight to manage potential risks and ensure appropriate use.

Q: Can INJECTRAN cause drowsiness or affect the ability to drive?

Official regulatory documents for this medication, which address the effects on the ability to drive or operate machinery, do not typically contain specific warnings about somnolence or drowsiness for this class of drug.

Q: Are there warnings in the official instructions about long-term or frequent use of INJECTRAN?

The official protocol defines the treatment as a finite and cyclic course. It mandates a rest period of at least six months before the initiation of a repeat course, which serves as a necessary restriction on frequent or continuous long-term use.

How to Store and Dispose of ИНЪЕКТРАН (Dextran Solution)

The official labeled storage requirements for unopened ИНЪЕКТРАН solution for infusion mandate that the product be kept at controlled room temperature, typically 20 C to 25 C. It is explicitly required to avoid freezing the solution, as this condition may cause precipitation and compromise product integrity. The product must remain in its original container until use and should be visually inspected; solutions that appear cloudy, discolored, or contain precipitate must not be administered.

Handling and Disposal

This medication is packaged as a single-use container; any portion of the solution that is not used immediately must be discarded. To meet mandatory safety standards, the product must be kept out of the sight and reach of children. The disposal of all unused or expired solution, as well as associated materials, must be conducted in accordance with local pharmaceutical waste regulations; the product should not be disposed of via household trash or wastewater systems.